

BIOCON GROUP

FACT SHEET

September - 2024

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			
(Rs. Crores)			
Particulars	Q2 FY 25	Q2 FY 24	Variance %
<u>INCOME</u>			
Generics	624	676	-8%
Biosimilars	2,182	1,969	11%
Research services	891	910	-2%
Inter-segment	(107)	(93)	15%
Revenue from operations #	3,590	3,462	4%
Other income	33	158	-79%
TOTAL REVENUE	3,623	3,620	0%
<u>EXPENDITURE</u>			
Material & Power costs	1,279	1,227	4%
Staff costs	746	530	41%
Research & Development expenses*	200	264	-24%
Other expenses	679	700	-3%
Manufacturing, staff & other expenses	2,905	2,721	7%
EBITDA	718	900	-20%
Interest & Finance charges	226	248	-9%
Depreciation & Amortisation	420	389	8%
Share of loss / (profit) in JV / Associate, net	-	24	-100%
PBT	72	238	-70%
Exceptional item	26	(24)	-
PBT	98	214	-54%
Taxes	47	46	3%
Taxes on exceptional item	4	(4)	-95%
Deferred tax charge on withdrawal of indexation benefit	20	-	100%
NET PROFIT BEFORE MINORITY INTEREST	27	173	-84%
Minority interest	38	51	-25%
Minority interest on exceptional item	5	(4)	-118%
NET PROFIT FOR THE PERIOD	(16)	126	-113%
EPS Rs.	(0.1)	1.0	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	(13)	142	-109%
Exceptional item, net of taxes	(3)	(16)	16%
NET PROFIT FOR THE PERIOD	(16)	126	-113%
<i># Licensing Income</i>	13	6	
<i>* Gross Research & Development expenses</i>	200	278	

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q2 FY 25	Q1 FY 25	Variance %
INCOME			
Generics	624	659	-5%
Biosimilars	2,182	2,083	5%
Research services	891	790	13%
Inter-segment	(107)	(100)	7%
Revenue from operations #	3,590	3,433	5%
Other income	33	1,134	-97%
TOTAL REVENUE	3,623	4,567	-21%
EXPENDITURE			
Material & Power costs	1,279	1,276	0%
Staff costs	746	702	6%
Research & Development expenses*	200	228	-12%
Other expenses	679	606	12%
Manufacturing, staff & other expenses	2,905	2,812	3%
EBITDA	718	1,755	-59%
Interest & Finance charges	226	236	-4%
Depreciation & Amortisation	420	405	4%
PBT BEFORE EXCEPTIONAL ITEM	72	1,114	-93%
Exceptional item, Net	26	32	-100%
PBT	98	1,146	-91%
Taxes	47	273	-83%
Taxes on exceptional item	4	11	-63%
Deferred tax charge on withdrawal of indexation benefit	20	-	100%
NET PROFIT BEFORE MINORITY INTEREST	27	862	-97%
Minority interest	38	192	-80%
Minority interest on exceptional item	5	10	-
NET PROFIT FOR THE PERIOD	(16)	660	-102%
EPS Rs.	(0.1)	5.5	
NET PROFIT BEFORE EXCEPTIONAL ITEM	(13)	648	-102%
Exceptional item	(3)	12	
NET PROFIT FOR THE PERIOD	(16)	660	-102%
<i># Licensing Income</i>	13	6	
<i>* Gross Research & Development expenses</i>	200	228	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	H1 FY 25	H1 FY24	Variance %
INCOME			
Generics	1,284	1,377	-7%
Biosimilars	4,265	3,984	7%
Research services	1,681	1,718	-2%
Inter-segment	(206)	(194)	6%
Revenue from operations #	7,023	6,885	2%
Other income	1,137	251	352%
TOTAL REVENUE	8,160	7,136	14%
EXPENDITURE			
Material & Power costs	2,555	2,551	0%
Staff costs	1,449	1,050	38%
Research & Development expenses*	428	579	-26%
Other expenses	1,255	1,250	0%
Manufacturing, staff & other expenses	5,687	5,429	5%
EBITDA	2,473	1,707	45%
Interest & Finance charges	462	481	-4%
Depreciation & Amortisation	825	747	10%
Share of loss / (profit) in JV / Associate, net	-	57	100%
PBT BEFORE EXCEPTIONAL ITEM	1,186	422	181%
Exceptional item, Net	58	(24)	-
PBT	1,244	398	213%
Taxes	320	81	297%
Taxes on exceptional item	15	(4)	
Deferred tax charge on withdrawal of indexation benefit	20	-	0%
NET PROFIT BEFORE MINORITY INTEREST	889	322	176%
Minority interest	231	99	135%
Minority interest on exceptional item	14	(4)	-
NET PROFIT FOR THE PERIOD	644	227	184%
EPS Rs.	5.4	1.9	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	635	243	161%
Exceptional item, net of taxes	9	(16)	
NET PROFIT FOR THE PERIOD	644	227	184%
<i># Licensing Income</i>	19	173	
<i>* Gross Research & Development expenses</i>	428	601	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	Sep 30, 2024	Mar 31, 2024
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,462	7,418
(b) Capital work-in-progress	4,354	3,985
(c) Right-of-use assets	637	575
(d) Goodwill	16,467	16,372
(e) Other intangible assets	6,024	6,279
(f) Intangible assets under development	4,201	4,008
(g) Investment in associates and a joint venture	-	-
(g) Financial assets		
Investments	1,253	684
Derivative assets	171	266
Other financial assets	179	147
(i) Income tax asset, net	458	413
(j) Deferred tax asset, net	221	317
(k) Other non-current assets	547	428
Non-current assets	41,974	40,892
Current assets		
(a) Inventories	4,965	4,944
(b) Financial assets		
Investments	556	316
Trade receivables	6,129	6,231
Cash and cash equivalents	1,688	1,234
Other bank balances	407	1,025
Derivative assets	138	138
Other financial assets	467	577
(c) Other current assets	804	715
Current assets	15,154	15,180
TOTAL - ASSETS	57,128	56,072
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	20,393	19,183
Equity attributable to owners of the Company	20,993	19,783
Non-controlling interests	5,727	5,491
Total Equity	26,720	25,274
Non-current liabilities		
(a) Financial liabilities		
Borrowings	11,822	12,932
Lease liabilities	520	492
Derivative liabilities	19	-
Other financial liabilities	1,158	1,073
(b) Other non-current liabilities	308	311
(c) Provisions	226	238
(d) Deferred tax liability, net	391	392
Non-current liabilities	14,444	15,438
Current liabilities		
(a) Financial liabilities		
Borrowings	4,328	2,797
Lease liabilities	101	55
Trade payables	6,369	6,272
Derivative liabilities	2	1
Other financial liabilities	4,215	5,001
(b) Other current liabilities	473	777
(c) Provisions	208	180
(d) Income tax liability, net	268	277
Current liabilities	15,964	15,360
TOTAL - EQUITY AND LIABILITIES	57,128	56,072